Annual conference 2024 – on demand access for HCP’s
New for 2024, HEART UK are pleased to announce pay-on-demand access for HCPs to access presentations from the 37th Annual Medical & Scientific conference 2024.
This selection of videos will be available until the end of December 2024.
To access:
1. Click Here
2. Click “Register account”
3. Select your HCP level
4. Enter your card details
5. Select the HCP level - Other HCP's - £160.00 / Qualified Doctor - £210.00
On demand talks available:
Wednesday 10 July
SESSION ONE | Welcome + International Perspectives
- Dyslipidemia and Cardiovascular Disease: A Global Perspective Implementable policies to increase awareness, diagnostic, access and adherence to treatments on a global scale. Dr Jean-Luc Eiselé (Geneva, Switzerland)
- International challenges for cardiovascular prevention around lipids. Results of the INTERASPIRE study in 14 countries across all 6 WHO regions Lipids management worldwide falls well below guideline standards, with enormous heterogeneity in outcomes between countries Prof Kornelia Kotseva (London, UK)
SESSION TWO | NICE v European Guidelines
- Understanding NICE & ESC Guideline Differences Prof Riyaz Patel (London, UK)
- LDL-C calculation – What comes next after Friedewald? Dr Alan Remaley (Bethesda, Maryland, USA)
SESSION THREE | Joint session with BIHS
- How low should we go with blood pressure treatment? Dr Kazem Rahimi (Oxford, UK)
- How should I manage hypertension in my clinic Dr Pankaj Gupta (Leicester, UK)
SESSION FIVE | Managing hypertriglyceridaemia: What is new?
- Atherosclerosis and pancreatitis in familial vs. multifactorial chylomicronaemia – insights from the FCS UK register Dr Charlotte Dawson (Birmingham, UK) Management of chylomicronaemia syndromes, what is new? Prof Handrean Soran (Manchester, UK)
Thursday 11 July
SESSION SIX | Women and CVD
- Empowering change: The EAS call to action on women, lipids and CVD It is essential to identify and treat modifiable cardiovascular risk factors earlier in women, especially for those at risk due to sex-specific conditions, to reduce the unacceptably high burden of ASCVD in women. Prof Jeanine Roeters van Lennep (Rotterdam, The Netherlands)
SESSION SEVEN | Paediatrics
- Unlocking the Future; Familial Hypercholesterolaemia and the Newborn Genomes Programme What are the potential benefit and possible drawbacks of identifying families with FH by whole genome sequencing of a newborn baby? Prof Steve Humphries (London, UK)
- Navigating paediatric Homozygous FH management Management challenges of Homozygous Familial Hypercholesterloaemia in childhood Dr Mike Champion (London, UK)
- Challenges in Paediatric Homozygous FH Management, Insights from Sheffield A case study based presentation highlighting the challenges faced in managing children with Homozygous Familial Hypercholesterolaemia. Miss Nichola Cowie (Sheffield, UK)
SESSION EIGHT | Diet and Lifestyle
- Panel discussion on the dietary management of metabolic lipid conditions Dr Alan Flanagan (Surrey, UK) Dr Kofi Antwi (Bristol, UK) Mr Simon Tapley (Bristol, UK)
- Charting success: an update on HEART UK’s Diet Quizzes to support the dietary management of cholesterol Presenting the results from HEART UK's newly updated online dietary assessment tool. The revised diet quizzes provide consumers with tailored and realistic dietary advice, encouraging them to review their diet regularly. Ms Elphee Medici (London, UK)
SESSION NINE - Abstracts of free communications | Medical & Scientific
- FC 1 - Genetic Landscape of Familial Chylomicronaemia Syndrome (FCS) and Multifactorial Chylomicronaemia Syndrome (MCS) in United Kingdom Bilal Bashir (University of Manchester, UK)
- FC 2 The long-term, real-world effectiveness and safety of lomitapide in homozygous familial hypercholesterolaemia (HoFH): Nine-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER) Jaimini Cegla (Imperial College Healthcare NHS Trust, London, UK)
- FC 3 Variants in LPA are associated with mutation-negative Familial Hypercholesterolaemia: whole genome sequencing analysis in the 100,000 Genomes Project Marta Futema (University College London, UK)
- FC 4 HMGCoAR autoantibodies: hidden in plain sight? Gavin Mercer-Smith (Newcastle upon Tyne Hospitals NHSFT, Newcastle upon Tyne, UK)
- FC 5 Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials Alexis Llewellyn (University of York, UK)
SESSION NINE - Abstracts of free communications | Primary & Healthcare
- FC 6 Challenges and opportunities for identifying people with Familial Hypercholesterolaemia in the UK: Evidence from the National FH PASS database Edward Cox (University of York, UK)
- FC 7 Bempedoic acid: real-world efficacy and tolerability in lipid clinics across three UK Centres Agnieszka Jakubowska (East and North Hertfordshire NHS Trust, Stevenage, UK)
- FC 8 Lomitapide in paediatric patients with homozygous familial hypercholesterolaemia (HoFH) – Analysis of patient-level LDL-C reduction, fat soluble vitamins, lipoproteins and patient maturation from the APH-19 study Zsuzsanna Tamas (Chiesi Pharmaceuticals, Bois-Colombes, France)
- FC 9 Hypertriglyceridaemia and Cardiovascular Autonomic Function in Patients Without Diabetes Mellitus Bilal Bashir (University of Manchester, UK)
- FC 10 Clinical Service Quality and Unmet Needs in Homozygous Familial Hypercholesterolaemia Patients: Insights from UK Tertiary Centres Raabya Pasha (University of Manchester, UK)
SESSION TEN - Keynote Myant lecture:
- An International Perspective on Models of Care for FH International experience on gaps in care for FH will be reviewed and clinical and implementation guidance for closing these gaps will be presented based on contemporary evidence. Prof Gerald Watts (Perth, AUSTRALIA)
Friday 12 July
- Clinical Lipidology Live Live patient case studies and discussion Facilitator: Prof Dev Datta